Heysek Randy V
Radiation Oncology Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
Cancer Control. 2007 Jul;14(3):238-43. doi: 10.1177/107327480701400306.
Prostate cancer is the most common cancer diagnosed in men. An increasing number of these patients are seeking minimally invasive procedures such as transperineal interstitial permanent radioactive seed prostate brachytherapy.
This paper reviews the historical perspective and the current advances in transperineal interstitial permanent radioactive seed prostate brachytherapy. The 10- to 15-year results data now published for brachytherapy alone or in combination with external-beam irradiation are also reviewed.
Modern brachytherapy using transperineal interstitial permanent radioactive seed prostate brachytherapy offers patients an excellent quality of life with convenient outpatient treatment with long-term (10- to 15-year) biochemical relapse-free survival rates ranging from 67% to 87%, depending on risk stratification.
Modern-day brachytherapy utilizing either radioactive iodine-125 or palladium-103 alone or in combination with supplemental external-beam treatment offers patients a successful treatment outcome with acceptable toxicity.
前列腺癌是男性中最常被诊断出的癌症。越来越多的这类患者正在寻求微创治疗方法，如经会阴间质永久性放射性粒子前列腺近距离放射治疗。
本文回顾了经会阴间质永久性放射性粒子前列腺近距离放射治疗的历史背景和当前进展。还回顾了现在已发表的单独使用近距离放射治疗或与外照射联合使用的10至15年的结果数据。
使用经会阴间质永久性放射性粒子前列腺近距离放射治疗的现代近距离放射治疗为患者提供了良好的生活质量，门诊治疗方便，长期（10至15年）生化无复发生存率根据风险分层在67%至87%之间。
单独使用放射性碘-125或钯-103或与补充外照射联合使用的现代近距离放射治疗为患者提供了具有可接受毒性的成功治疗结果。
